PTC Therapeutics (NASDAQ:PTCT) Stock Gets Price Target Bump from TD Cowen

Key Points

• TD Cowen raised PTC Therapeutics’ price target to $95 from $90 and maintained a “buy” rating, implying 58.41% upside from the prior close. The broader analyst consensus is “Moderate Buy,” with an average target of $95.64.
• PTC shares fell 7.0% to $59.97, near their 12-month low, after the company reported a GAAP loss of $0.62 per share versus expectations for $0.14 in earnings.
• Despite the profitability miss, quarterly revenue rose 69.6% year over year to $357.81 million, exceeding estimates of $306.43 million and highlighting continued growth in the company’s rare-disease business.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) had its target price boosted by investment analysts at TD Cowen from $90.00 to $95.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. TD Cowen's price target would indicate a potential upside of 58.41% from the stock's previous close.

A number of other equities analysts also recently issued reports on PTCT. Weiss Ratings raised shares of PTC Therapeutics from a "sell (d)" rating to a "sell (d+)" rating in a report on Thursday, October 8th. Barclays increased their price objective on shares of PTC Therapeutics from $120.00 to $122.00 and gave the stock an "overweight" rating in a research report on Friday, August 14th. Wall Street Zen downgraded shares of PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Saturday, October 10th. Royal Bank Of Canada lifted their price target on PTC Therapeutics from $75.00 to $77.00 and gave the stock a "sector perform" rating in a research report on Friday. Finally, Morgan Stanley upped their target price on PTC Therapeutics from $93.00 to $104.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, PTC Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $95.64.

PTC Therapeutics Stock Down 7.0%

Shares of NASDAQ:PTCT traded down $4.49 during midday trading on Friday, reaching $59.97. 2,347,947 shares of the company traded hands, compared to its average volume of 1,348,979. The firm's fifty day moving average price is $65.57 and its two-hundred day moving average price is $70.87. The firm has a market capitalization of $5.01 billion, a price-to-earnings ratio of -103.40, a price-to-earnings-growth ratio of 1.90 and a beta of 0.49. PTC Therapeutics has a 12 month low of $58.80 and a 12 month high of $90.87.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of $0.14 by ($0.76). The business had revenue of $357.81 million for the quarter, compared to analyst estimates of $306.43 million. PTC Therapeutics's revenue was up 69.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.20 EPS. Analysts forecast that PTC Therapeutics will post 1.19 earnings per share for the current year.

Insider Transactions at PTC Therapeutics

In related news, VP Mark Boulding sold 2,813 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.57, for a total transaction of $204,139.41. Following the transaction, the vice president owned 105,272 shares of the company's stock, valued at $7,639,589.04. This represents a 2.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew B. Klein sold 10,292 shares of the business's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $68.57, for a total value of $705,722.44. Following the sale, the chief executive officer directly owned 383,868 shares in the company, valued at $26,321,828.76. This trade represents a 2.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 77,370 shares of company stock worth $5,322,261. 5.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Allworth Financial LP acquired a new stake in PTC Therapeutics during the second quarter valued at approximately $67,000. EverSource Wealth Advisors LLC raised its stake in PTC Therapeutics by 16.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 151 shares during the period. Harbor Investment Advisory LLC purchased a new stake in shares of PTC Therapeutics during the 2nd quarter worth about $81,000. Quantbot Technologies LP acquired a new position in PTC Therapeutics during the second quarter valued at approximately $112,000. Finally, GAMMA Investing LLC grew its stake in shares of PTC Therapeutics by 58.1% in the second quarter. GAMMA Investing LLC now owns 1,453 shares of the biopharmaceutical company's stock worth $119,000 after acquiring an additional 534 shares during the last quarter.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Analysts raised their price targets. Wells Fargo increased its target to $112 from $109 and maintained an “overweight” rating, while RBC raised its target to $77 from $75 but retained a “sector perform” rating. The new targets imply substantial potential upside from recent trading levels. Analyst price target changes
• Positive Sentiment: PTC raised its full-year 2026 outlook. The company now expects total revenue of $1.29 billion to $1.32 billion and product revenue of $960 million to $990 million. Third-quarter revenue reached approximately $358 million, up 69.6% year over year and well above the roughly $306 million consensus estimate. PTC Therapeutics third-quarter results
• Positive Sentiment: Sephience commercialization remained a major growth driver. The product generated $182 million in third-quarter revenue, supported by continued U.S. growth and international expansion. PTC also acquired ST-920, a Fabry disease gene therapy, and expects to complete its Biologics License Application submission in the fourth quarter of 2026.
• Neutral Sentiment: Analyst commentary and the earnings call highlighted strong operating performance and business expansion, but investors are likely to focus on whether the revenue growth can translate into sustainable earnings and cash flow. Third-quarter earnings call transcript
• Negative Sentiment: Profitability was the key disappointment. PTC reported a GAAP loss of $0.62 per share, versus consensus expectations for earnings of $0.14 per share. Although adjusted earnings were reported by some data providers at $0.61 per share, the headline GAAP loss and sharply lower year-over-year earnings likely pressured the stock.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company's commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.